A

A-41988
  in glaucoma 183
Absolute glaucoma 183
Absorption
  re nutrition and psychoactive drugs 85
Acebutolol
  in glaucoma 183
Acetazolamide
  in glaucoma 183
  re advances in the Japanese pharmaceutical industry 357
Acetylpheneturide
  re advances in the Japanese pharmaceutical industry 357
AD-810
  re advances in the Japanese pharmaceutical industry 357
Adrenergic agents
  in glaucoma 183
Adrenocorticotrophin
  during sexual cycle 328
Amitriptyline
  re advances in the Japanese pharmaceutical industry 357
Angiotensin II
  cardiovascular effects upon central administration 168
  central site of action 168
  hemodynamic effects 171
  physiological significance 173
Anterioventral third ventricle
  re centrally administered angiotensin II 168
Antianxiety drugs
  re advances in the Japanese pharmaceutical industry 357
Antidepressants
  neurophysiological criteria 255
    waking EEG 255
    evoked potentials 256
    sleep polygrams 257
  performance criteria 236
  physiological criteria 244
  prediction of therapeutic usefulness from experiments on healthy persons 217
  re advances in the Japanese pharmaceutical industry 357
  subjective criteria 226
Antidiuretic hormone
  re centrally administered angiotensin II 168
Antiepileptic drugs
  re advances in the Japanese pharmaceutical industry 357
Antiparkinson agents
  re advances in the Japanese pharmaceutical industry 357
Antipsychotic drugs
  re advances in the Japanese pharmaceutical industry 357
Anxiety
  re advances in the Japanese pharmaceutical industry 357
Apomorphine-induced emesis in dogs
  neuroleptic drug action on 49
Area postrema
  re centrally administered angiotensin II 168
Aqueous humor
  in glaucoma 183
Atenolol
  in glaucoma 183
Attia, M.A. Ovarian steroids and pituitary function in some experimental animals and in man 327
Autonomic activity
  re assessment of psychotropic drugs on 344

B

Barrows, C.H. and Kokkonen, G.C. Genetic information and the life-span of laboratory animal models 293
Behavioural studies
  collective analysis 27
Behavioural tests for neuroleptic drug action
  antagonism of locomotor hyperactivity induced by intracerebral dopamine 22
  drug-induced catalepsy 6
  inhibition of brain self-stimulation 15
  inhibition of circling behaviour 17
  inhibition of climbing behaviour 19
  inhibition of discriminated and non-discriminated response 13
  inhibition of drug-induced stereotypy 9
  inhibition of dyskinetic phenomena 25

Bemegride
re advances in the Japanese pharmaceutical industry 357
Benperidol
re advances in the Japanese pharmaceutical industry 357
Benzodiazepines
re advances in the Japanese pharmaceutical industry 357
Beta-blockers
in glaucoma 183
Biochemical tests for neuroleptic drug action
increased formation of dopamine metabolites 35
inhibition of dopamine release 38
inhibition of dopamine stimulated adenylate cyclase 39
receptor labelling assays 42
Buckley, J.P. Cardiovascular effects of centrally administered angiotensin II 168

C

Calcium hopatenate
re advances in the Japanese pharmaceutical industry 357
Cannabinoids
in glaucoma 183
Cannabinol acetate
in glaucoma 183
Carbachol
in glaucoma 183
Carbamazepine
re advances in the Japanese pharmaceutical industry 357
Carbohydrates
re nutrition and psychoactive drugs 85
Carbonic anhydrase inhibitors
in glaucoma 183
Carpipramine
re advances in the Japanese pharmaceutical industry 357
CDP-choline
re advances in the Japanese pharmaceutical industry 357
Central nervous system
mechanisms in hypertension 168
mechanisms in IOP 109
Cerebral insufficiency improvers
re advances in the Japanese pharmaceutical industry 357
Cerebral palsy
re advances in the Japanese pharmaceutical industry 357
Chlordiazepoxide
re advances in the Japanese pharmaceutical industry 357
Chlorimipramine
re advances in the Japanese pharmaceutical industry 357
Chlorpromazine
re advances in the Japanese pharmaceutical industry 357
Cholinergic agents
in glaucoma 183
Choroid
in glaucoma 183
Ciliary body
in glaucoma 183
Ciliary zonules
in glaucoma 185
Citicholine
re advances in the Japanese pharmaceutical industry 357
Clocarpramine
re advances in the Japanese pharmaceutical industry 357
Clonidine
administration by different routes 128
animal experiments 122
central administration 126
clinical experiments 121
effects following pretreatment with piperoxane 138
effects in ganglionectomized cat 135
in therapy of glaucoma simplex 121
in treatment of glaucoma 183
on IOP 119
mechanisms in lowering IOP 121
mydriasis induced by 139
Closed-angle glaucoma 183
Clotiazepam
re advances in the Japanese pharmaceutical industry 357
Cloxazolam
re advances in the Japanese pharmaceutical industry 357

Clozapine
re advances in the Japanese pharmaceutical industry 357
Consciousness disturbance
re advances in the Japanese pharmaceutical industry 357
Cornea
in glaucoma 183
Cortisol
re advances in the Japanese pharmaceutical industry 357
Costall, B. and Naylor, R. J. Assessment of the test procedures used to analyse neuroleptic action 4
Cyclohexamine
re genetic information and life-span in laboratory animal models 293

D

DD-3480
re advances in the Japanese pharmaceutical industry 357
Delta-9-THC
in glaucoma 183
Demecarium bromide
in glaucoma 183
Developmental glaucoma 183
Depression
re advances in the Japanese pharmaceutical industry 357
Diazepam
re advances in the Japanese pharmaceutical industry 357
Dichloroisoproteronol
in glaucoma 183
Dichlorpenamide
in glaucoma 183
Diet
re genetic information and life-span in laboratory animal models 293
Dimetacrine
re advances in the Japanese pharmaceutical industry 357
Diphenylhydantoin
re advances in the Japanese pharmaceutical industry 357
Dipivefrin
in glaucoma 183
Dopamine
re assessment of neuroleptic drugs 4
Dopamine function in periphery
neuroleptic drug action on 47
Down's syndrome
re advances in the Japanese pharmaceutical industry 357
Drug-induced glaucoma 183

E

Echothiopate iodide
in glaucoma 183
Electrophysiology
re predicting therapeutic usefulness of psychotropic drugs from experiments on healthy persons 215
Encephalopathy
re advances in the Japanese pharmaceutical industry 357
Endocrine systems
neuroleptic drug action on 54
Enzymes
re genetic information and life-span in laboratory animal models 293
Epilepsy
re advances in the Japanese pharmaceutical industry 357
Epinephrine
in glaucoma 183
Estazolam
re advances in the Japanese pharmaceutical industry 357
Estevez, V.S.; see Ho, B.T. and Estevez, V.S. Nutrition and psychoactive drugs 85
Ethoxazolamide
in glaucoma 183
Exfoliation glaucoma 183
Extrapyramidal effects
re advances in the Japanese pharmaceutical industry 357
Eye
in glaucoma 183

F

Fludiazepam
re advances in the Japanese pharmaceutical industry 357
Fecundity
re genetic information and life-span in laboratory animal models 293

G

GABA
re advances in the Japanese pharmaceutical industry 357
Glaucoma
anatomy and physiology of 184
associated with hereditary or familial diseases 183
classification of 187
primary 188
secondary 188
developmental 189
diagnosis of 185
pharmacological treatment of
adrenergic drugs in 195
B-blockers in 198
cannabinoids in 204
carbonic anhydrase inhibitors in 197
cholinergic drugs in 192
Glycerine
in glaucoma 183
Growth hormone
during sexual cycle 328

H

Haloperidol
re advances in the Japanese pharmaceutical industry 357
Haloxazolam
re advances in the Japanese pharmaceutical industry 357
Healthy subjects
re assessment of the therapeutic usefulness of psychotropic drugs 215
Hemiplegia
re advances in the Japanese pharmaceutical industry 357
Hemolytic glaucoma 183
Ho, B.T. and Estevez, V.S.
Nutrition and psychoactive drugs 85
Howes, J.F.; see Razdan, Raj K. and Howes, J.F., Recent advances in the pharmacological treatment of glaucoma 183
Hyperactivity
re advances in the Japanese pharmaceutical industry 357
Hypertension
re centrally administered angiotensin II 168
Hypnotics
re advances in the Japanese pharmaceutical industry 357
Hypobulia
re advances in the Japanese pharmaceutical industry 357

I

ID-622
re advances in the Japanese pharmaceutical industry 357
ID-4708
re advances in the Japanese pharmaceutical industry 357
ID-9206
re advances in the Japanese pharmaceutical industry 357
Imipramine
re advances in the Japanese pharmaceutical industry 357
Infantile glaucoma 183
Inflammatory glaucoma 183
Inorganic elements
re nutrition and psychoactive drugs 85
Innemee, H.C. and van Zwieten, P. A.
The central nervous influence of drugs on intraocular pressure 109
Insomnia
re advances in the Japanese pharmaceutical industry 357
Intraocular pressure (IOP)
clonidine on 119
administration by different routes 128
animal experiments 122
central administration 126
clinical experiments 121
effects following pretreatment with piperoxane 138
effects in ganglionectomized cat 135
in therapy of glaucoma simplex 120
mechanism in lowering IOP 121
mydriasis induced by 139
factors controlling 183
non-pharmacological techniques in 110
pharmacological techniques in 115

ceutical industry 357
Neurosis
re advances in the Japanese pharmaceutical industry 357
Neurotransmitters
re assessment of the autonomic effects of psychotropic drugs in man 344
Nimetazepam
re advances in the Japanese pharmaceutical industry 357
Nitrazepam
re advances in the Japanese pharmaceutical industry 357
Nootropics
re advances in the Japanese pharmaceutical industry 357
Nutrition
re psychoactive drugs 86
absorption 86
distribution and uptake 88
metabolism 90
urinary excretion 97

O

Ocusert
in glaucoma 183
Oestrogens
during sexual cycle 332
Oestrogen-progestogen combination
during sexual cycle 332
Open-angle glaucoma 183
Optic nerve
in glaucoma 183
Osmotic agents
in glaucoma 183
Ovarian steroids
during sexual cycle 328
Oxazolam
re advances in the Japanese pharmaceutical industry 357

P

P-5257
re advances in the Japanese pharmaceutical industry 357
P-6127
re advances in the Japanese pharmaceutical industry 357
p-chlorophenylalanine
re advances in the Japanese pharmaceutical industry 357
Pantothenate
re advances in the Japanese pharmaceutical industry 357
Paradoxical sleep
re advances in the Japanese pharmaceutical industry 357
Parkinsonians
re advances in the Japanese pharmaceutical industry 357
Perphenazine
re advances in the Japanese pharmaceutical industry 357
PF-257
re advances in the Japanese pharmaceutical industry 357
Phacogenic glaucoma 183
Pharmacopsychiatry
re predicting therapeutic usefulness of psychotropic drugs in experiments on healthy persons 215
Phenacemide
re advances in the Japanese pharmaceutical industry 357
Phenobarbital
re advances in the Japanese pharmaceutical industry 357
Physostigmine
in glaucoma 183
Pigmentary glaucoma 183
Pilocarpine
in glaucoma 183
Pindolol
in glaucoma 183
Pipamerone
re advances in the Japanese pharmaceutical industry 357
Piroheptine
re advances in the Japanese pharmaceutical industry 357
Pituitary gland hormones
during sexual cycle 328
Platelets
in assessment of the autonomic effects of psychotropic drugs in man 343
monoamine uptake, storage and release 345
platelet aggression 345
Practolol
in glaucoma 357
Primary congenital glaucoma 183
Primary glaucoma 183

Progestogens
during sexual cycle 328
Prolactin
during sexual cycle 328
Promethazine
re advances in the Japanese pharmaceutical industry 357
Pronethalol
in glaucoma 183
Propranolol
in glaucoma 183
Proteins
re nutrition and psychoactive drugs 85
Psychoactive drugs
re nutrition 85
absorption 86
distribution and uptake 88
metabolism 90
urinary excretion 97
Psychomotor seizure
re advances in the Japanese pharmaceutical industry 357
Psychosomatic patients
re advances in the Japanese pharmaceutical industry 357
Psychotropic drugs
antidepressants 226
methods used to assess autonomic effects in man 344
cardiovascular system 346
heart rate 347
high speed surface ECG 349
plethysmography 347
pressor responses 348
skin temperature 347
superficial hand vein 346
isolated human tissue 344
platelets 344
smooth muscle 344
neurological system 349
accomodation 350
intraocular pressure 350
micturation 351
pupil diameter 350
salivary volume 349
sweating 351
tremor 351
predicting therapeutic usefulness from experiments on healthy persons 215
neurological criteria 253
waking EEG 253
evoked potentials 254
sleep polygrams 255
performance criteria 234
physiological criteria 243
subjective criteria 223
neuroleptics 223
sedatives and hypnotics 221
stimulants 222
tranquilizers 227

R

Razdan, Raj., K, and Howes, J.F., Recent advances in pharmacoiogical treatment of glaucoma 183
Retina
in glaucoma 183
Rotifer
as an animal model for life-span genetic information experiments 293

S

Schizophrenia
re advances in the Japanese pharmaceutical industry 357
Schlemm's canal
in glaucoma 183
Sclera
in glaucoma 183
Secondary glaucoma 183
Sedatives and hypnotics
predicting therapeutic usefulness from experiments on healthy persons 217
Neurophysiological criteria 248
waking EEG 248
evoked potentials 248
sleep polygrams 249
performance criteria 231
physiological criteria 241
subjective criteria 221
Serotonin
re nutrition and psychoactive drug 85
Sleep
re advances in the Japanese pharmaceutical industry 357
SP-106
in glaucoma 183

tetrahydrocannabinol on
cardiovascular changes induced by 145
effects on IOP in the anaesthetized cat 150
intravenous administration 150
pontomedullary administration 155
effects on intraocular hydro- and hemodynamics 147
ocular hypotensive effect of 145
literature on central IOP lowering effect of 150
mechanism in lowering blood pressure 145
timilol on 155
Intraventricular
re centrally administered angiotensin II 168
Iris: anatomy and neurophysiology
in glaucoma 183
Ischemia
re advances in the Japanese pharmaceutical industry 357
Isorenin-angiotensin system in brain
re centrally administered angiotensin II 168

K

Kokkonen, G.C.,: see Barrows, C.H. and Kokkonen, G.C., Genetic information and the life-span of laboratory animal models 293

L

Labetol
in glaucoma 183
Lamina cribrosa
in glaucoma 183
L-DOPA
re advances in the Japanese pharmaceutical industry 357
L-5-HTP
re advances in the Japanese pharmaceutical industry 357
Life-span
re genetic information in laboratory animal models 293
Lipids
re nutrition and psychoactive drugs 85

M

MAO
re advances in the Japanese pharmaceutical industry 357
Management of glaucoma 183
Mannitol
in glaucoma 183
Maprotiline
re advances in the Japanese pharmaceutical industry 357
Marihuana plant
in glaucoma 183
MCI-2016
re advances in the Japanese pharmaceutical industry 357
Mental retardation
re advances in the Japanese pharmaceutical industry 357
Methazolamide
in glaucoma 183
Metoclopramide
re advances in the Japanese pharmaceutical industry 357
Metropolol
in glaucoma 183
Mexazolam
re advances in the Japanese pharmaceutical industry 357
Minor tranquilizers
re advances in the Japanese pharmaceutical industry 357

N

Nabilone
in glaucoma 183
Nabitan
in glaucoma 183
Nakamura, K., Recent advances in psychotropic drugs in the Japanese pharmaceutical industry 357
Narrow-angle glaucoma 183
Naylor, R.J., see Costall, B. and Naylor, R.J., Assessment of the test procedures used to analyze neuroleptic action 4
Neovascular glaucoma 183
Neuroleptics
behavioural tests for 35
biochemical tests for 57
re advances in the Japanese pharma-

SP-204
in glaucoma 183
SPA-229
in glaucoma 183
Spiclomazine
re advances in the Japanese pharmaceutical industry 357
Spiegel, R., On predicting therapeutic usefulness of psychotropic drugs from experiments in healthy persons 215
Stimulants
predicting therapeutic usefulness from experiments on healthy persons 217
neurophysiological criteria 250
waking EEG 250
evoked potentials 251
sleep polygrams 252
performance criteria 232
physiological criteria 242
subjective criteria 222
Stroke
re advances in the Japanese pharmaceutical industry 357
Subfornicle organ
re centrally administered angiotensin II 168
Subnucleus medialis
re centrally administered angiotensin II 168
Sulpiride
re advances in the Japanese pharmaceutical industry 357

T

Temperature
re genetic information and life-span of laboratory animal models 293
Tetrahydrocannabinol
analogs in glaucoma 183
cardiovascular changes induced by 145
effects on IOP in the anaesthetized cat 150
intravenous administration 150
pontomedullary administration 150
effects on intraocular hydro- and hemodynamics 147
mechanisms of action in glaucoma 183
ocular hypotensive effects of 145
literature on central IOP lowering effect 148
mechanism in lowering blood pressure 145
Thioridazine
re advances in the Japanese pharmaceutical industry 357
Timilol
in glaucoma 183
in treatment of altered IOP 155
Tolmalol
in glaucoma 183
Trabecular meshwork
in glaucoma 183
Tranquilizers
predicting therapeutic usefulness from experiments on healthy persons 217
neurophysiological criteria 258
waking EEG 258
evoked potentials 259
sleep polygrams 259
performance criteria 237
physiological criteria 245
subjective criteria 227
TRH tartrate
re advances in the Japanese pharmaceutical industry 357
Traumatic glaucoma 183
Triazolam
re advances in the Japanese pharmaceutical industry 357
Trifluperidol
re advances in the Japanese pharmaceutical industry 357
Trihexyphenidyl
re advances in the Japanese pharmaceutical industry 357
Turner, P., Some methods to assess the autonomic effects of psychotropic drugs in man 343

U

Urea
in glaucoma 183
Uvea
in glaucoma 183

V

van Zwieten, P.A.: see Innemee, H.C. and van Zwieten, P.A., The central nervous influence of drugs on intraocular pressure 109
Vasopressin
re advances in the Japanese pharmaceutical industry 357
Viloxazine
re advances in the Japanese pharmaceutical industry 357
Vitamins
re nutrition and psychoactive drugs 85
Vitreous body
in glaucoma 183

W

Wide-angle glaucoma 183

Y

Y-7131
re advances in the Japanese pharmaceutical industry 357
Y-9179
re advances in the Japanese pharmaceutical industry 357
YM-08050
re advances in the Japanese pharmaceutical industry 357
Ym-08054-1
re advances in the Japanese pharmaceutical industry 357